Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.31 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489158 | 0.88 | ACHE (0.44) | ACHEBACE1 | |
| SCHEMBL16489153 | 0.81 | ACHE (0.53) | ACHEBACE1MAOAALDH1A2ALDH1A1 | |
| SCHEMBL29507295 | 0.70 | ACHE (0.53) | ACHEBACE1 | |
| SCHEMBL16491912 | 0.69 | ACHE (0.50) | ACHEBACE1 | |
| SCHEMBL30011553 | 0.69 | ACHE (0.57) | ACHEBACE1ALDH1A1 | |
| SCHEMBL29717643 | 0.69 | ACHE (0.57) | ACHEBACE1ALDH1A1 | |
| SCHEMBL30018961 | 0.68 | ACHE (0.46) | ACHEBACE1ALDH1A1 | |
| SCHEMBL16489152 | 0.67 | HTT (0.30) | ALDH1A2ALDH1A1ALDH2ALDH1B1ALDH1A3 | |
| SCHEMBL8899137 | 0.65 | HTR2A (0.40) | ACHEMAOA | |
| SCHEMBL7581528 | 0.59 | ACHE (0.47) | ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9668985-B2 | Pterosin derivative-containing therapeutic preparation for disease associated with cartilage loss, cartilage degeneration and/or cartilage thinning | KYOTO UNIVERSITY (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20150051293-A1 | PTEROSIN DERIVATIVE-CONTAINING THERAPEUTIC PREPARATION FOR DISEASE ASSOCIATED WITH CARTILAGE LOSS, CARTILAGE DEGENERATION AND/OR CARTILAGE THINNING | KYOTO UNIVERSITY (JP) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051293-A1 | PTEROSIN DERIVATIVE-CONTAINING THERAPEUTIC PREPARATION FOR DISEASE ASSOCIATED WITH CARTILAGE LOSS, CARTILAGE DEGENERATION AND/OR CARTILAGE THINNING | SYVN1, ADAMTS5, ADAMTS1 | ACHE 4558/4885BACE1 4867/4885MAOA 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.